IM Cannabis (IMCC) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
31 Mar, 2026Executive summary
Achieved revenue of C$54.7 million for 2025, demonstrating stability amid challenges in Israel.
Generated positive operating cash flow of C$4.7 million, a turnaround from negative cash flow in 2024.
Germany revenue grew over 134% year-over-year to C$36.3 million, now over 66% of total revenue.
Announced intent to diversify into defense and intelligence technology sectors via proposed acquisition in Poland.
Financial highlights
Gross profit increased 15% to C$9.7 million, driven by cost efficiencies and higher-margin German sales.
Cash and restricted cash rose to C$3.3 million from C$927,000 at year-end 2024.
Strengthened cash position through a private placement yielding net proceeds of C$5.1 million.
Outlook and guidance
Exploring additional business activities to enhance long-term growth, including entry into defense and homeland security technology.
Proposed acquisition of 51% of Black Axe Technologies in Poland marks strategic expansion.
Latest events from IM Cannabis
- Q4 revenue up 25% and Germany sales soared 183%, driving positive adjusted EBITDA.IMCC
Q4 202417 Mar 2026 - Convertible note and warrant offering targets German growth but poses dilution and geopolitical risks.IMCC
Registration Filing5 Feb 2026 - German sales surged 129% post-legalization, but margin pressure led to a CAD 3.5M net loss.IMCC
Q2 20241 Feb 2026 - Revenue up 12% and adjusted EBITDA loss down 82%, driven by German growth and efficiency.IMCC
Q3 202413 Jan 2026 - Seeking up to $50M for expansion, with focus on Germany and ongoing risks in Israel.IMCC
Registration Filing16 Dec 2025 - Resale of nearly 5M shares enables capital for growth in Germany and Israel, with Nasdaq listing.IMCC
Registration Filing16 Dec 2025 - Refocused on Germany’s medical cannabis market, with growth funded by recent private placements.IMCC
Registration Filing16 Dec 2025 - Profitability and margin growth in Q1 2025, led by German gains and cost reductions.IMCC
Q1 202519 Nov 2025 - Stable revenue but higher net loss in Q3 2025 due to impairment and margin decline.IMCC
Q3 202513 Nov 2025